StockData
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Immuneering Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.66+0.07 (+1.95%)

Close on Oct 19, 2026

Market cap
$236.79M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 11, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 5, 2026Before market open–––
Q1 FY2026
Ended Mar 31, 2026
May 15, 2026Before market open–––
Q4 FY2025
Ended Dec 31, 2025
Mar 6, 2026Before market open–––
Q3 FY2025
Ended Sep 30, 2025
Nov 12, 2025During market hours–––
Q2 FY2025
Ended Jun 30, 2025
Aug 13, 2025During market hours–$-0.40–
Q1 FY2025
Ended Mar 31, 2025
May 5, 2025During market hours–––
Q4 FY2024
Ended Dec 31, 2024
Mar 20, 2025During market hours–––
Q3 FY2024
Ended Sep 30, 2024
Nov 13, 2024During market hours–$-0.49–
Q2 FY2024
Ended Jun 30, 2024
Aug 6, 2024During market hours–$-0.47–
Q1 FY2024
Ended Mar 31, 2024
May 7, 2024During market hours–$-0.49–
Q4 FY2023
Ended Dec 31, 2023
Mar 1, 2024Before market open–$-0.52–

Press releases

Announcements Immuneering filed with the SEC